📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
226 announcements match the current filters (relevance ≥ 5).
Apollo Pipes to Merge Kisan Mouldings; Announces 4.96:100 Share Swap Ratio
Apollo Pipes Limited (APL) has approved a two-step merger involving KML Tradelinks and Kisan Mouldings (KML) into itself. Under the scheme, APL will issue 4.96 equity shares for every 100 shares held in KML, expanding its equity base from 4.40 crore to 4.63 crore shares. The merger integrates KML's ₹250.07 crore turnover business with APL's ₹887.44 crore operations to achieve operational synergies and economies of scale. Post-merger, APL's promoter holding will slightly decrease from 51.72% to 49.20%.
Key Highlights
Share swap ratio set at 4.96 equity shares of Apollo Pipes for every 100 shares of Kisan Mouldings.
Consolidates Kisan Mouldings' ₹250.07 Cr turnover and ₹148.65 Cr net worth into Apollo Pipes.
Apollo Pipes' total equity share capital to increase to 4,63,03,174 shares post-merger.
Promoter shareholding in the combined entity will be 49.20%, down from 51.72% pre-merger.
The merger aims to integrate the 'KISAN' brand and optimize logistics and distribution networks.
👀 What to Watch
Investors should view this as a positive consolidation that enhances Apollo Pipes' market share and product portfolio in the piping industry. Monitor the regulatory and NCLT approval timeline for completion of the merger.
Apollo Pipes to Merge Kisan Mouldings; Swap Ratio Set at 4.96:100
Apollo Pipes (APL) has approved a two-step merger involving its subsidiary Kisan Mouldings (KML) and KML's subsidiary KML Tradelinks. The deal involves a share swap ratio where KML shareholders will receive 4.96 shares of APL for every 100 shares held in KML. This consolidation aims to integrate the 'KISAN' brand, achieve operational synergies, and scale the combined turnover, which stood at ₹1,137.51 Cr (pro-forma) for FY26. Post-merger, APL's promoter holding will slightly decrease from 51.72% to 49.20%.
Key Highlights
Share swap ratio fixed at 4.96 equity shares of Apollo Pipes for every 100 shares of Kisan Mouldings.
Combined FY26 turnover of APL (₹887.44 Cr) and KML (₹250.07 Cr) reaches approximately ₹1,137.5 Cr.
Promoter holding in Apollo Pipes to adjust from 51.72% to 49.20% post-amalgamation.
Integration of 'KISAN' and 'KML CLASSIC' brands into Apollo Pipes' portfolio to enhance market reach.
The Appointed Date for the scheme is April 01, 2026, subject to NCLT and regulatory approvals.
👀 What to Watch
Investors should view this as a strategic consolidation that brings the 'Kisan' brand under one roof and improves operational scale. Monitor the progress of regulatory approvals and the impact on consolidated margins post-integration.
Apollo Hospitals Shareholders Approve Composite Scheme of Arrangement with 90.44% Majority
Apollo Hospitals Enterprise Limited (AHEL) has received approval from its equity shareholders, secured creditors, and unsecured creditors for a composite scheme of arrangement. The scheme involves the integration of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech to streamline the pharmacy and digital health business. The resolution was passed with a significant majority, with 90.44% of total equity votes cast in favor. This restructuring is a critical step in the company's long-term strategy to consolidate its pharmacy distribution and digital health ecosystem.
Key Highlights
Equity shareholders approved the scheme with 11.01 crore votes (90.44%) in favor and 1.16 crore votes (9.56%) against.
Public institutional investors showed 85.69% support for the resolution, while public non-institutional support was higher at 96.96%.
Promoter and promoter group voted 100% in favor of the arrangement with 4.02 crore votes.
The scheme involves a composite arrangement between AHEL, Apollo Healthco, Keimed Private Limited, and Apollo Healthtech.
The meetings were held on June 24, 2026, following directions from the NCLT Chennai Bench.
👀 What to Watch
Investors should view this as a positive milestone toward the successful restructuring of Apollo's pharmacy and digital health business. Continue to monitor for final NCLT sanctions and the subsequent impact on the valuation of the Apollo 24/7 platform.
Apollo Hospitals Shareholders Approve Composite Scheme of Arrangement with 90.44% Majority
Apollo Hospitals Enterprise Limited (AHEL) has received shareholder and creditor approval for its composite scheme of arrangement involving Apollo Healthco, Keimed Private Limited, and Apollo Healthtech. In the court-convened meeting held on June 24, 2026, the resolution was passed with a significant 90.44% majority of the total votes polled. Public institutional shareholders supported the move with an 85.69% 'in favor' vote, while promoters voted 100% in favor. This restructuring is a key step in consolidating the company's pharmacy distribution and digital health platforms.
Key Highlights
Composite scheme of arrangement approved by shareholders, secured creditors, and unsecured creditors with requisite majority.
Total votes polled amounted to 12.17 crore, with 11.01 crore votes (90.44%) cast in favor of the resolution.
Public institutional support was strong at 85.69%, while non-institutional public shareholders voted 96.96% in favor.
The scheme involves the integration of Keimed Private Limited and Apollo Healthco into the resultant entity, Apollo Healthtech.
The voting was conducted via remote e-voting and electronic voting during the meeting held on June 24, 2026.
👀 What to Watch
Investors should view this as a positive milestone in the company's efforts to streamline its health-tech and pharmacy businesses. The focus now shifts to final NCLT approvals and the eventual impact on consolidated margins and valuation.
Apollo Hospitals Concludes NCLT Meetings for Restructuring Scheme with Keimed and Healthco
Apollo Hospitals Enterprise Limited (AHEL) successfully conducted NCLT-mandated meetings on June 24, 2026, to approve a composite scheme of arrangement. The scheme involves the integration of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech Limited to streamline the group's pharmacy distribution and digital health segments. While the secured creditors meeting proceeded smoothly, the unsecured creditors meeting required a 30-minute adjournment to achieve the necessary quorum. This procedural milestone is a critical step toward final regulatory approval for the group's restructuring.
Key Highlights
Meetings held on June 24, 2026, for secured creditors, unsecured creditors, and equity shareholders via video conferencing.
Composite scheme involves Apollo Hospitals (Demerged Co), Apollo Healthco (Transferor 1), Keimed (Transferor 2), and Apollo Healthtech (Resultant Co).
Unsecured creditors meeting was adjourned for 30 minutes from 11:00 a.m. to 11:30 a.m. due to initial lack of quorum.
Remote e-voting was conducted from June 20 to June 23, 2026, with additional voting provided during the meetings.
Final voting results under SEBI Regulation 44(3) are pending and will be submitted separately.
👀 What to Watch
Investors should monitor the upcoming disclosure of voting results to confirm stakeholder approval and track the timeline for final NCLT sanctioning of the scheme.
Apollo Hospitals Holds NCLT-Convened Meetings for Composite Scheme of Arrangement
Apollo Hospitals Enterprise Limited (APOLLOHOSP) conducted NCLT-convened meetings on June 24, 2026, for its secured creditors, unsecured creditors, and equity shareholders. The meetings were held to seek approval for a composite scheme of arrangement involving Apollo Healthco Limited, Keimed Private Limited, and Apollo Healthtech Limited. While the unsecured creditors' meeting required a 30-minute adjournment to meet quorum requirements, all proceedings were successfully concluded via video conferencing. The final voting results, which will determine the progress of this corporate restructuring, are expected to be released separately.
Key Highlights
Meetings held on June 24, 2026, for Secured Creditors (10:00 AM), Unsecured Creditors (11:00 AM), and Equity Shareholders (2:30 PM).
The proposed scheme involves the merger/arrangement of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech with the parent company.
Unsecured Creditors meeting was adjourned for 30 minutes due to initial lack of quorum but reconvened at 11:30 AM per NCLT directions.
Remote e-voting was conducted from June 20 to June 23, 2026, with additional e-voting provided during the meetings.
The scheme is being processed under Sections 230 to 232 of the Companies Act, 2013, following NCLT orders dated March, April, and May 2026.
👀 What to Watch
Investors should watch for the upcoming disclosure of the formal voting results to confirm if the scheme has received the necessary majority approval from all stakeholder classes.
Apollo Micro Systems Allots 21.43 Lakh Equity Shares; Raises Rs 18.32 Crore via Warrant Conversion
Apollo Micro Systems Limited has allotted 21,43,095 equity shares of Re. 1 each following the conversion of warrants by three investors: Reena Karwa, Superstar Investments Private Limited, and Trikaya Wealth Advisors Pvt Ltd. The company received Rs. 18.32 crore as the warrant exercise price, which represents the remaining 75% of the total issue price of Rs. 114 per warrant. This allotment completes the conversion process for the total 3,80,67,058 warrants originally issued in June 2025. As a result, the company's paid-up share capital has increased to Rs. 37.16 crore.
Key Highlights
Allotment of 21,43,095 equity shares upon conversion of warrants at an issue price of Rs. 114 per share.
Inflow of Rs. 18.32 crore as the final 75% exercise price from three specific allottees.
Total paid-up capital increased to Rs. 37,15,99,512 consisting of 37,15,99,512 equity shares of Re. 1 each.
Successful completion of the conversion for the entire batch of 3,80,67,058 warrants issued on a preferential basis in 2025.
👀 What to Watch
Investors should view this as a positive capital infusion that strengthens the balance sheet, though they should account for the minor equity dilution. Monitor the company's upcoming quarterly results to see how this additional capital is deployed for growth.
Apollo Tyres Announces ₹2.50 Dividend for FY26; Sets Record Date for July 10, 2026
Apollo Tyres Limited has recommended a final dividend of ₹2.50 per equity share of ₹1 each for the financial year 2025-26. The dividend is subject to shareholder approval at the 53rd Annual General Meeting scheduled for July 29, 2026. The company has fixed July 10, 2026, as the record date to determine eligibility for the payout. Additionally, the company provided detailed guidelines on Tax Deduction at Source (TDS) rates, ranging from 10% to 20% depending on PAN availability and residency status.
Key Highlights
Recommended a final dividend of ₹2.50 per equity share for FY26.
Fixed Friday, July 10, 2026, as the record date for dividend entitlement.
The 53rd Annual General Meeting (AGM) is scheduled for July 29, 2026, via video conferencing.
TDS of 10% applies to resident shareholders with valid PAN if the dividend exceeds ₹10,000.
Deadline for submitting tax exemption documents to the RTA is Monday, July 13, 2026.
👀 What to Watch
Investors should ensure their PAN and bank account details are updated with their Depository Participant or RTA by July 10 to ensure seamless dividend credit. Eligible shareholders should submit tax exemption forms by July 13 to avoid higher TDS.
Apollo Hospitals Clarifies Governance for Healthtech Listing; Promoter Rights Lapse Below 10%
Apollo Hospitals has issued clarifications regarding the governance structure of Apollo Healthtech Limited, the entity to be independently listed following a composite scheme of arrangement. The company has established a 10% fall-away threshold for aggregate promoter nomination rights and a 5% threshold for individual promoter entities. Additionally, a tiered board representation system has been introduced, limiting the number of nominee directors based on shareholding percentages. These measures, including a commitment to 50% board independence under an executive chairperson, aim to address stakeholder concerns and improve transparency.
Key Highlights
Promoter and promoter group will waive all director nomination rights if aggregate shareholding falls below 10%.
Individual promoter entities will lose nomination rights if their specific holding falls below 5%.
Tiered nomination rights established: 2 directors for 10-15% stake, up to 5 directors for 35% or more stake.
Commitment to maintain at least 50% independent directors on the board if an executive chairperson is in place.
The scheme involves the arrangement of Apollo Healthco and Keimed Private Limited into Apollo Healthtech for independent listing.
👀 What to Watch
Investors should view these governance clarifications as a positive step toward institutional-grade management for the new entity. Continue to monitor the timeline for the independent listing of Apollo Healthtech as it represents a significant value-unlocking event for AHEL shareholders.
Apollo Tyres Sets July 10 as Record Date for Final Dividend; 53rd AGM on July 29
Apollo Tyres Limited has scheduled its 53rd Annual General Meeting (AGM) for July 29, 2026, to be held via video conferencing. The company has fixed July 10, 2026, as the record date for determining shareholder eligibility for the final dividend for the financial year ended March 31, 2026. Shareholders must hold shares by this date to receive the dividend, which will be paid within 30 days of the AGM approval. Additionally, the e-voting period for AGM resolutions is set from July 26 to July 28, 2026.
Key Highlights
53rd Annual General Meeting scheduled for Wednesday, July 29, 2026, at 3:00 PM IST.
Record date for final dividend eligibility fixed as Friday, July 10, 2026.
Remote e-voting period spans from July 26, 2026 (10:00 AM) to July 28, 2026 (5:00 PM).
Cut-off date for e-voting and participation eligibility is July 22, 2026.
Final dividend to be disbursed within 30 days of the AGM, subject to shareholder approval.
👀 What to Watch
Investors seeking the final dividend should ensure they hold the stock before the record date of July 10, 2026. Shareholders should also review the Annual Report for FY26 once released to evaluate the company's performance and future guidance.
Apollo Tyres Sets July 10, 2026, as Record Date for Final Dividend
Apollo Tyres Limited has announced July 10, 2026, as the record date to determine shareholder eligibility for the final dividend for the financial year ended March 31, 2026. The 53rd Annual General Meeting (AGM) is scheduled for July 29, 2026, where the dividend will be formally declared. Eligible shareholders will receive the payment within 30 days of the AGM date. The company has also outlined e-voting timelines, with the voting window open from July 26 to July 28, 2026.
Key Highlights
Record date for final dividend eligibility is fixed for July 10, 2026.
53rd Annual General Meeting (AGM) to be held on July 29, 2026, at 3:00 PM IST.
Dividend payment will be processed within 30 days of shareholder approval at the AGM.
Remote e-voting for shareholders will take place between July 26 and July 28, 2026.
Cut-off date for e-voting eligibility is July 22, 2026.
👀 What to Watch
Investors seeking to qualify for the final dividend should ensure they hold the company's shares in their demat account before the record date of July 10, 2026. Monitor the AGM results on July 29 for the final confirmation of the dividend payout amount.
Apollo Micro Systems Allots 87.65 Lakh Shares, Raising ₹74.95 Crore via Warrant Conversion
Apollo Micro Systems Limited has approved the allotment of 87,65,615 equity shares following the conversion of warrants issued on a preferential basis. The company received ₹74.95 crore as the warrant exercise price, representing the 75% balance of the ₹114 issue price per warrant. Major allottees include Ebisu Global Opportunities Fund Limited, which converted over 82.45 lakh warrants. This move increases the company's total paid-up equity capital to approximately ₹36.95 crore.
Key Highlights
Allotted 87,65,615 equity shares of face value Re. 1 each upon conversion of warrants.
Received aggregate consideration of ₹74,94,60,082.50 as the balance exercise price.
Ebisu Global Opportunities Fund Limited was the primary allottee, converting 82,45,615 warrants.
Total warrants converted to date reach 3,59,23,963 out of the 3,80,67,058 warrants originally issued.
Paid-up share capital increased from ₹36.07 crore to ₹36.95 crore following this allotment.
👀 What to Watch
Investors should view the capital infusion as a positive for the company's liquidity and balance sheet strength, while remaining aware of the marginal equity dilution resulting from the increased share count.
Apollo Hospitals Clarifies Healthtech Scheme: 50% Independent Board & 4x MOIC Upside Target
Apollo Hospitals has provided additional governance and financial clarifications regarding the composite scheme of arrangement involving Apollo Healthco, Keimed, and Apollo Healthtech. The proposed Apollo Healthtech board will consist of 50% independent directors (6 members) and includes a 10% fall-away threshold for promoter and investor nomination rights. A key feature is an investor-funded 'Upside Agreement' that rewards management with up to 9% of the upside if a 4x Multiple of Invested Capital (MOIC) is achieved, ensuring no cash outflow from the company. This restructuring aims to unlock value through the independent listing of Apollo Healthtech as a focused healthcare platform.
Key Highlights
Apollo Healthtech board will feature 50% independent representation with 6 independent directors and a Lead Independent Director.
Investor-funded Upside Agreement provides a maximum 9% reward contingent on achieving a minimum 4x MOIC target.
Promoter and investor board nomination rights will lapse if their respective shareholding falls below a 10% threshold.
Ms. Shobana Kamineni is proposed as Executive Chairperson of the new entity, subject to NCLT and shareholder approvals.
The scheme is designed as a composite unified transaction to integrate Apollo Healthco and Keimed for strategic agility.
👀 What to Watch
Investors should support the scheme as it clarifies governance standards and aligns management incentives with significant value creation targets (4x MOIC) without financial burden to the company. Monitor the upcoming NCLT-convened shareholder meetings for formal approval of the arrangement.
Apollo Micro Systems allots 33.85 lakh shares; raises ₹28.94 Cr via warrant conversion
Apollo Micro Systems Limited has allotted 33,85,362 equity shares of Re. 1/- each following the exercise of warrants by six investors, including Ebisu Global Opportunities Fund Limited. The company received ₹28.94 crore as the warrant exercise price, representing the remaining 75% of the ₹114 issue price per warrant. To date, 2,71,58,348 warrants have been converted out of the 3,80,67,058 warrants originally issued in June 2025. This conversion has increased the company's total paid-up share capital to ₹36.07 crore.
Key Highlights
Allotment of 33,85,362 equity shares upon conversion of warrants at an issue price of ₹114 per share.
Receipt of ₹28,94,48,451 as the balance 75% exercise price from six specific allottees.
Ebisu Global Opportunities Fund Limited was the largest participant in this tranche, converting 17,54,385 warrants.
Total warrants converted to date reach 2,71,58,348 out of the 3,80,67,058 warrants initially issued.
Post-allotment, the company's paid-up capital stands at ₹36,06,90,802 consisting of 36,06,90,802 equity shares.
👀 What to Watch
Investors should note the successful capital infusion and institutional interest from Ebisu Global, though they should also account for the gradual equity dilution as the remaining warrants are converted.
Apollo Micro Systems Allots 33.85 Lakh Equity Shares on Warrant Conversion; Raises ₹28.94 Cr
Apollo Micro Systems Limited has approved the allotment of 33,85,362 equity shares following the conversion of warrants previously issued on a preferential basis. The company received ₹28,94,48,451 as the warrant exercise price, representing the remaining 75% of the ₹114 issue price per warrant. This conversion involves six allottees, including Ebisu Global Opportunities Fund Limited. Consequently, the company's paid-up capital has increased to ₹36.07 crore, comprising 36,06,90,802 equity shares.
Key Highlights
Allotment of 33,85,362 equity shares of Re. 1/- each upon conversion of warrants.
Total capital infusion of ₹28.94 crore received as warrant exercise price at ₹85.50 per share.
Total issue price per warrant was ₹114, with this tranche representing the final 75% payment.
Post-allotment paid-up share capital increased to ₹36,06,90,802.
Out of 3.80 crore warrants originally issued, 2.71 crore warrants have been converted to date.
👀 What to Watch
Investors should note the successful capital infusion and the conversion of warrants by institutional and individual investors as a sign of confidence. Monitor the company's deployment of these funds into its core defense and electronics business.
Gujarat Apollo Recommends Rs 2 Final Dividend; Approves FY26 Audited Financial Results
Gujarat Apollo Industries has recommended a final dividend of Rs 2 per equity share (20% of face value) for FY 2025-26, subject to shareholder approval. The Board also approved the audited financial results for the quarter and year ended March 31, 2026, with auditors issuing an unmodified opinion. The company reported zero defaults on loans and disclosed the utilization of Rs 34.16 crore raised through a preferential issue in October 2025. Additionally, M/s. S.K Moondra & Co. has been appointed as the Internal Auditor for the upcoming financial year.
Key Highlights
Recommended a final dividend of Rs 2 per equity share (20% on face value of Rs 10) for FY 2025-26.
Approved audited standalone and consolidated financial results for the year ended March 31, 2026, with a clean audit report.
Disclosed zero outstanding defaults on loans or debt securities as of the reporting date.
Utilized Rs 36.53 crore (including issue expenses) from preferential issue proceeds for expansion and working capital.
Appointed M/s. S.K Moondra & Co. as Internal Auditors for the financial year 2026-27.
👀 What to Watch
Investors should monitor the upcoming Annual General Meeting for dividend approval and review the detailed financial results to assess the impact of recent expansion plans funded by the preferential issue. The clean audit report and zero-debt default status are positive indicators of financial health.
Gujarat Apollo Recommends ₹2 Dividend and Approves Audited FY26 Results
Gujarat Apollo Industries Limited has recommended a dividend of ₹2 per equity share (20% of face value) for the financial year 2025-26. The Board approved the audited standalone and consolidated financial results for the year ended March 31, 2026, with a clean (unmodified) audit opinion. The company also reported zero financial indebtedness and provided an update on the utilization of ₹34.16 crore raised via a preferential issue in October 2025. M/s. S.K Moondra & Co. has been appointed as the Internal Auditor for FY 2026-27.
Key Highlights
Recommended a dividend of ₹2 per equity share (20% on face value of ₹10) for FY 2025-26.
Reported zero total financial indebtedness including short-term and long-term debt as of March 31, 2026.
Utilized ₹34.16 crore raised from a preferential issue for expansion, working capital, and capital expenditure.
Received an unmodified audit opinion from statutory auditors for both standalone and consolidated FY26 results.
Appointed M/s. S.K Moondra & Co. as Internal Auditors for the financial year 2026-27.
👀 What to Watch
Investors should monitor the upcoming Annual General Meeting for dividend approval and review the detailed financial statements for growth metrics. The debt-free status and consistent dividend payout reflect a stable financial position.
Apollo Hospitals Schedules NCLT-Convened Meeting for Composite Scheme on June 24, 2026
Apollo Hospitals Enterprise Limited has announced an NCLT-convened meeting on June 24, 2026, to seek shareholder approval for a composite scheme of arrangement. The scheme involves the restructuring and integration of Apollo Healthco Limited, Keimed Private Limited, and Apollo Healthtech Limited. Remote e-voting for shareholders will be available from June 20 to June 23, 2026, with a cut-off date of June 17, 2026. The approval requires a three-fourths majority in value of the voting shareholders and a majority of public shareholders to pass.
Key Highlights
NCLT-convened meeting for equity shareholders scheduled for June 24, 2026, at 2:30 PM via VC/OAVM.
Remote e-voting period set from June 20, 2026 (9:00 AM) to June 23, 2026 (5:00 PM).
Cut-off date for determining voting eligibility is June 17, 2026.
Quorum for the equity shareholders' meeting is fixed at 35,640 members.
Scheme requires approval from 75% in value of voting shareholders and a majority of public shareholders.
👀 What to Watch
Investors should review the scheme of arrangement details to understand the impact of the Keimed and Healthco integration on the company's valuation. Shareholders are advised to cast their votes during the e-voting window ending June 23.
Apollo Hospitals Schedules NCLT-Convened Meetings for Composite Scheme on June 24, 2026
Apollo Hospitals Enterprise Limited (AHEL) has announced NCLT-convened meetings for equity shareholders and creditors on June 24, 2026, to approve a composite scheme of arrangement. The scheme involves the restructuring of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech. For the scheme to proceed, it requires approval from a majority of shareholders representing three-fourths in value of those voting. Additionally, the scheme is conditional upon the votes cast by public shareholders in favor exceeding those cast against it.
Key Highlights
NCLT-convened meetings for equity shareholders scheduled for June 24, 2026, at 2:30 PM via VC/OAVM.
Composite scheme involves Apollo Hospitals, Apollo Healthco, Keimed Private Limited, and Apollo Healthtech.
Approval requires a 75% majority in value of the equity shareholders present and voting.
Cut-off date for determining voting eligibility is June 17, 2026, with remote e-voting from June 20 to June 23.
Quorum for the equity shareholders' meeting is specifically set at 35,640 members.
👀 What to Watch
Investors should evaluate the long-term impact of integrating Keimed and the pharmacy business restructuring on AHEL's margins. Monitor the voting results expected within two working days of the June 24 meeting for confirmation of shareholder support.
Apollo Micro Systems Reports Record FY26 Revenue of ₹904 Cr, PAT Jumps 91% YoY
Apollo Micro Systems delivered its highest-ever annual performance in FY26, with consolidated revenue growing 61% to ₹904 crores and PAT surging 91% to ₹107 crores. The company's order book stands robust at ₹1,432 crores, providing strong future visibility for the coming fiscal years. Management highlighted a strategic shift toward becoming a global OEM by 2036, supported by a significant 8% R&D spend and new licenses for advanced defense platforms including UAVs and missiles.
Key Highlights
Consolidated revenue for FY26 reached ₹904 crores, a 61% increase from ₹562 crores in FY25.
Net profit (PAT) for the full year grew by 91% to ₹107 crores, with Q4 FY26 PAT surging 164% YoY to ₹37 crores.
Order book as of March 31, 2026, stands at ₹1,432 crores, ensuring strong revenue visibility.
R&D expenditure reached ₹72 crores (8% of revenue) focusing on AI, RF systems, and inertial navigation.
EBITDA margins expanded to 24% in FY26, a 500 basis point improvement over the last five years.
👀 What to Watch
Investors should maintain a positive outlook given the strong order book and margin expansion; monitor the execution of the 'Vision 2036' strategy as the company transitions to a global OEM.
